Solid Biosciences granted Andelyn Biosciences a non‑exclusive worldwide license to use AAV‑SLB101, Solid’s next‑generation capsid engineered for enhanced skeletal muscle and cardiac tropism with reduced liver biodistribution. The agreement enables Andelyn to offer the capsid through its AAV Curator® modular CDMO platform, broadening access for early‑stage gene therapy programs. Solid highlighted SLB101’s clinical validation from the INSPIRE DUCHENNE trial and said the license supports broader vector availability while preserving Solid’s existing licensing and collaboration footprint. The move aims to lower manufacturing barriers for developers seeking differentiated capsids for muscle and cardiac indications.